TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03869229

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular injection of ADMSC
Description: Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)- ultrasound guided intra-articular injection of at least 10 million of ADMCS per procedure, maximum four procedures (i.e. injections per joint), minimum number of cells pre protocol 40 million

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular injection of ADMSC
Description: Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)- ultrasound guided intra-articular injection of at least 10 million of ADMCS per procedure, maximum four procedures (i.e. injections per joint), minimum number of cells pre protocol 40 million

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular injection of ADMSC
Description: Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)- ultrasound guided intra-articular injection of at least 10 million of ADMCS per procedure, maximum four procedures (i.e. injections per joint), minimum number of cells pre protocol 40 million
Study: NCT02804958

Intervention type: PROCEDURE
Intervention: STEMI treated with primary PCI
Description: Primary percutaneous coronary intervention was performed according to the current standard guidelines. Coronary angiography was performed using standard techniques. The use of thrombectomy devices, intravascular ultrasound, intra-aortic balloon pump, and percutaneous cardiopulmonary support was up to the operator.
Study: NCT01327534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: treatment with a 60 mg loading dose prasugrel, followed by a maintenance dose of 10 mg for 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: treatment with a 600 mg loading dose clopidogrel, followed by a maintenance dose of 75 mg for 30 days
Study: NCT00437489

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Human Insulin (Exubera)
Description: Initial dose (mg) as per weight based formula = 0.05 x body weight (kg) TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Human Insulin (Exubera)
Description: Initial dose of 1mg TID of inhaled human insulin
Study: NCT02449824

Intervention type: OTHER
Intervention: magnetic resonance imaging
Description: early MRI
Study: NCT02893722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atosiban
Description: give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion in total dose of 37.5 mg is set in certain infusion rate, and complete the infusion in 3 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion is set in the same rate with experimental group, complete the infusion in 3 hours.
Study: NCT02175446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and eribulin
Description: In this study, Bevacizumab and Eribulin are considered to be the investigational study drugs. Bevacizumab is provided as 25 mg/ml concentrate for infusion. Vials contain 100 mg of Bevacizumab in 4 ml and/or 400 mg in 16 ml. Eribulin is provided as vials containing 1 mg/2 mL Eribulin as a 500 µg/mL solution in ethanol/water
Study: NCT01098448

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scaling and root planing
Description: scaling and root planing as a single therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local tetracycline
Description: local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets \>5mm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: systemic metronidazole and amoxicillin
Description: systemic metronidazole (250 mg tid x 14) and amoxicillin (500 mg bid x 14

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: surgery
Description: periodontal surgery in residual pockets of \>4mm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local antibiotics and systemic metronidazole and amoxicillin
Description: 1.7 mg/tooth tetracycline fiber plus metronidazole (250 mg tid x14d)and amoxicillin (500 mg bid x 14d)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local tetracycline and periodontal surgery
Description: local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets \>5mm and periodontal surgery in residual pockets of \>4mm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: periodontal surgery and systemic metronidazole and amoxicillin
Description: surgery in residual pockets \>4mm and metronidazole (250mg tidx14d) and amoxicillin (500mg bidx14d)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: surgery, local tetracycline, systemic metronidazole and amoxicillin
Description: periodontal surgery in residual pockets \>4mm, tetracycline ibers releasing approximately 1.7 mg/tooth in pockets \>5mm, systemic metronidazlo (250mg tidx14d) and amoxicillin (500 mg bidx14d)
Study: NCT02567266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Outcomes Questionnaire
Description: The YOQ consists of parent- and youth-report measures of symptoms and alliance administered weekly on a tablet computer. The YOQ online system then generates reports to provide clinicians with systematic feedback about client progress, flagging critical items that have been endorsed (e.g., suicidality, hallucinations), presenting graphs of ratings over time, and providing empirically-derived alerts when clients are failing to progress or showing deterioration. Clinicians will be trained to use this feedback to modify treatment as needed, share it with families as appropriate, and use it to enhance use of supervision.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Clinicians assigned to the TAU condition will be instructed to use whatever treatment methods and outcome monitoring strategies they typically use with adolescents with internalizing disorders.
Study: NCT03973190

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ISQ analysis
Description: The prosthetic component already installed. On it is adapted the SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden). According to the manufacturer, the device generates a series of signals with different frequencies in Hertz (Hz) and these values are immediately converted to ISQ (Implantation Stability Coefficient), providing fast and accurate monitoring. The calibration is performed on the buccal and palatal surfaces of the intermediaries, that is, each implant was submitted to 2 readings. The readings were captured and tabulated for further analysis. were repeated at intervals of 7 to 10 days, 30 days and 60 days, for evaluation of SSI in the period of osseointegration. With the objective of not subjecting the implant to torque and torque during this period and to avoid interfering with the osseointegration process, the micro-pillars were covered with the micro-pillar protection screws with digital pressure only.
Study: NCT02567266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Clinicians assigned to the TAU condition will be instructed to use whatever treatment methods and outcome monitoring strategies they typically use with adolescents with internalizing disorders.
Study: NCT03973190

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ISQ analysis
Description: The prosthetic component already installed. On it is adapted the SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden). According to the manufacturer, the device generates a series of signals with different frequencies in Hertz (Hz) and these values are immediately converted to ISQ (Implantation Stability Coefficient), providing fast and accurate monitoring. The calibration is performed on the buccal and palatal surfaces of the intermediaries, that is, each implant was submitted to 2 readings. The readings were captured and tabulated for further analysis. were repeated at intervals of 7 to 10 days, 30 days and 60 days, for evaluation of SSI in the period of osseointegration. With the objective of not subjecting the implant to torque and torque during this period and to avoid interfering with the osseointegration process, the micro-pillars were covered with the micro-pillar protection screws with digital pressure only.
Study: NCT02802345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nintedanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Study: NCT02754167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRS-080#022-DP
Description: Hepcidin antagonism to mobilize iron and to treat anemia

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PRS-080-Placebo#001
Description: Placebo comparator
Study: NCT01010321

Intervention type: DEVICE
Intervention: confocal microscopy
Description: non-invasive imaging
Study: NCT01692431

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA
Description: High fat meal containing EPA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA
Description: High fat meal containing DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: High fat meal containing negligible EPA/DHA content
Study: NCT02277639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACs device
Description: Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACs device
Description: Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells.
Study: NCT00831922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib (AB1010)
Description: 3 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib (AB1010)
Description: 6 mg/kg/day
Study: NCT04075383

Intervention type: PROCEDURE
Group type: OTHER
Intervention: immediate dental implant
Description: Replacement of a lost tooth with a titanium screw retained in the alveolar bone in the same session of tooth extraction.
Study: NCT03789422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: association of levocetirizine and tranexamic acid
Description: levocetirizine 10 mg/day + tranexamic acid 2 g/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine only
Description: levocetirizine 20 mg/day
Study: NCT00412087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol (vitamin D3)
Description: randomized to one of two treatments: 2000 or 4000 IU vitamin D3/day
Study: NCT04075383

Intervention type: PROCEDURE
Group type: OTHER
Intervention: immediate-delayed dental implant
Description: Replacement of a lost tooth with a titanium screw retained in the alveolar bone 8 weeks after tooth extraction.
Study: NCT03446079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Anti Aging Cream
Description: Primary Subjects will take a saliva based genetic test and apply a topical anti aging cream for 6 weeks.
Study: NCT00412087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol (vitamin D3)
Description: randomized to one of two treatments: 2000 or 4000 IU vitamin D3/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: randomized to one of 2 treatment doses: 2000 vs. 4000 IU/day vitamin D3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: randomized to one of 2 treatment doses: 2000 vs. 4000 IU/day vitamin D3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: cholecalciferol at 2000 or 4000 IU/day to be taken througout pregnancy. This follows the initial run-in dosing of 2000 IU/day starting at 12-weeks' gestation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: cholecalciferol at 2000 or 4000 IU/day to be taken througout pregnancy. This follows the initial run-in dosing of 2000 IU/day starting at 12-weeks' gestation.
Study: NCT03827629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.
Study: NCT04395885

Intervention type: OTHER
Intervention: Electronic questionnaire
Description: Assess the current sexuality according to the gender using sexual questionnaires for men and women were adapted from the Arabic validated version of the five-item International Index of Erectile Function which is a validated, multidimensional, self-administered questionnaire used for the clinical assessment of erectile dysfunction.and for female Arabic validated version of the Female Sexual Function Index

Intervention type: OTHER
Intervention: Electronic questionnaire
Description: Assess the current sexuality according to the gender using sexual questionnaires for men and women were adapted from the Arabic validated version of the five-item International Index of Erectile Function which is a validated, multidimensional, self-administered questionnaire used for the clinical assessment of erectile dysfunction.and for female Arabic validated version of the Female Sexual Function Index
Study: NCT03827629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.
Study: NCT04456985

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid and vitamin B12
Description: Take folic acid and VitB12 for 3 consecutive days before surgery

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: brown sugar aqueous
Description: take 20 ml of brown sugar aqueous solution with the same concentration as the intervention group 3 days before the operation
Study: NCT02236364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour, Bayer Healthcare, LLC
Description: Blood glucose measurement
Study: NCT03827629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Naloxone HCL Intramuscular (IM) Injection
Description: Participants received naloxone HCl IM injection following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Naloxone HCL Intramuscular (IM) Injection
Description: Participants received naloxone HCl IM injection following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Naloxone HCL Intramuscular (IM) Injection
Description: Participants received naloxone HCl IM injection following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Naloxone HCL Intramuscular (IM) Injection
Description: Participants received naloxone HCl IM injection following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Naloxone HCL Intramuscular (IM) Injection
Description: Participants received naloxone HCl IM injection following a 10 hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Naloxone HCL Intramuscular (IM) Injection
Description: Participants received naloxone HCl IM injection following a 10 hour fast.
Study: NCT02192437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sulfur amino acid restricted diet
Description: Methionine restricted diet: 70% or 90% restriction Methionine and cysteine restricted diet: 50% or 65% restriction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sulfur amino acid restricted diet
Description: Methionine restricted diet: 70% or 90% restriction Methionine and cysteine restricted diet: 50% or 65% restriction
Study: NCT03217045

Intervention type: OTHER
Intervention: nutrition protocol introduction
Description: Growth comparison of 2 cohorts of infants evaluated in a before-after design

Intervention type: OTHER
Intervention: nutrition protocol introduction
Description: Growth comparison of 2 cohorts of infants evaluated in a before-after design
Study: NCT04389840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dociparstat sodium
Description: Dociparstat is a glycosaminoglycan derived from porcine heparin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dociparstat sodium
Description: Dociparstat is a glycosaminoglycan derived from porcine heparin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dociparstat sodium
Description: Dociparstat is a glycosaminoglycan derived from porcine heparin.
Study: NCT02603159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine(Aibin)
Description: Capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 or 10 weeks in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine(Aibin)
Description: Capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 or 10 weeks in total

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
Study: NCT04389840

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Normal Saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Normal Saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Normal Saline
Study: NCT03321981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zenocutuzumab
Description: full length immunoglobulin gamma-1 (IgG1) bispecific antibody targeting Human Epidermal Growth Factor Receptor (HER)2 and HER3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zenocutuzumab
Description: full length immunoglobulin gamma-1 (IgG1) bispecific antibody targeting Human Epidermal Growth Factor Receptor (HER)2 and HER3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zenocutuzumab
Description: full length immunoglobulin gamma-1 (IgG1) bispecific antibody targeting Human Epidermal Growth Factor Receptor (HER)2 and HER3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: humanised IgG1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: humanised IgG1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: antineoplastic drug of vinca alkaloid family

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: same endocrine therapy is administered as the last line of endocrine therapy
Study: NCT03524222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Hospitalization
Description: See above
Study: NCT01022814

Intervention type: DEVICE
Intervention: A disposable pad containing sensitive chemical indicators
Description: After a urine/amniotic fluid leaking, liquid meets the diagnostic device and chemical reactions will occur in the test zones and cause a color change.
Study: NCT04098471

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transanal local excision following radiotherapy
Description: transanal local excision following radiotherapy
Study: NCT01592708

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antiemetic anesthesia protocol
Description: Intervention group consisted of patients undergoing maxillary osteotomy who received an antiemetic protocol designed to provide multimodal antiemetic therapy which have been shown to help prevent and/or treat postoperative nausea, combined with the elimination of anesthetic factors that may contribute to postoperative nausea and vomiting.
Study: NCT02962830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: intra-amniotic injection of 10 micrograms of Sufentanil
Study: NCT00856583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Description: Sertindole was supplied as 4, 12, 16, and 20 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national Summary of Product Characteristics (SPC) for sertindole; in countries where sertindole was not marketed, the European Union (EU) SPC applied (all national and EU SPCs were essentially identical). Recommended dose range: 12 to 20 mg/day. The investigators were instructed to contact H. Lundbeck A/S if they deemed it necessary to increase the dose of sertindole to 24 mg/day, which was allowed in exceptional cases

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone was supplied as 1, 2, 3, and 4 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national SPC for risperidone. Recommended dose range: 2 to 8 mg/day
Study: NCT02418325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells
Description: Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)